Thursday, May 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Industry News

PharmAthene Fulfills Anthrax Anti-Toxin Order

by Global Biodefense Staff
November 24, 2014
Anthrax Bacteria - Bacillus Anthracis

Anthrax Bacteria - Bacillus Anthracis

PharmAthene announced last week that it has fulfilled its obligations under a fixed price, indefinite delivery, indefinite quantity (IDIQ) contract, awarded in 2013 by the Biomedical Advanced Research and Development Authority (BARDA) for the Company’s anthrax anti-toxin, Valortim.

Under the IDIQ contract, PharmAthene was selected to provide a specified quantity of its Valortim anthrax anti-toxin master cell bank for secure storage by the government as part of a risk mitigation strategy for anthrax medical countermeasures.

PharmAthene is a biodefense company engaged in the development and commercialization of next generation medical countermeasures against biological and chemical threats. PharmAthene’s current biodefense portfolio includes the following candidates:

  • SparVax – a next generation recombinant protective antigen (rPA) anthrax vaccine (liquid and lyophilized formulations)
  • rBChE bioscavenger – a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides
  • Valortim – a fully human monoclonal antibody for the prevention and treatment of anthrax infection

In August 2014, the Delaware Court of Chancery issued a Memorandum Opinion and Order and awarded to PharmAthene lump sum expectation damages for the value of PharmAthene’s lost profits for SIGA Technologies, Inc.’s smallpox antiviral, Tecovirimat, also known as ST-246. In addition, the Court of Chancery ordered SIGA to pay pre-judgment interest and varying percentages of PharmAthene’s reasonable attorneys’ and expert witness fees.

A judgment, specifying the damages amount and fees payable to PharmAthene is expected to be issued by the Court of Chancery later this year and will remain subject to appeal.

Source: PharmAthene press release, adapted.

Tags: AnthraxAntitoxinsAntiviralsBARDABioscavengersBioterrorismStrategic National Stockpile

Related Posts

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster
Preparedness

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs
Medical Countermeasures

New Research on Building Blocks of Poxviruses Could Lead to Antiviral Drugs

April 10, 2022
Yersinia pestis
Funding News

NIH Awards $3M Grant to Albany Med for Plague Vaccine Development

April 8, 2022
Troubling Trends in Physician Vaccine Confidence in the United States
Medical Countermeasures

Troubling Trends in Physician Vaccine Confidence in the United States

April 5, 2022
Load More

Latest News

NIH to Further Invest in Point-of-Care Technologies Research Network

NIH to Further Invest in Point-of-Care Technologies Research Network

May 10, 2022

How a COVID-19 Infection Spurs Antibodies Against Common Colds

May 8, 2022
Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

Hospitals Resilience to Extreme Events: One-Third of Staff May Be Lost During a Disaster

May 6, 2022
Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

Where is Testing Needed Most During Pandemic Surges? WVU Researchers Develop Machine Learning Prediction Tools

May 6, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC